CSIMarket Company Name, Ticker, Competitors, else..


Bio rad Laboratories Inc   (BIO)
Other Ticker:  
 

Bio rad Laboratories Inc

BIO's Fundamental analysis



Bio Rad Laboratories Inc 's sales fell by -6.23 % in II. Quarter 2024 from the same quarter a year ago. Ranking at No. 813

Laboratory Analytical Instruments industry recorded deterioration of revenues by -4.39 %

Bio Rad Laboratories Inc net loss increased from $-1,162 millions, to $-2,165 millions in II. Quarter 2024,

• More on BIO's Growth


Bio Rad Laboratories Inc
realized a net loss in trailing twelve months.

Company is currently trading with Price to Cash flow multiple of 561.94 in trailing twelve-month period. Laboratory Analytical Instruments industry recorded net loss in trailing twelve months.
Company
-
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 3.78.
Laboratory Analytical Instruments industry's Price to Sales ratio is at 5.91.


• More on BIO's Valuation
 
 Total Debt (Millions $) 1,200
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Revenue/Employee (TTM) $ 319,017
 Net Income/Employee (TTM) $ -
 Receivable Turnover (TTM) 5.58
 Tangible Book Value (Per Share $) 213.40

Bio Rad Laboratories Inc
realized net loss in trailing twelve months.

Company is currently trading with Price to Cash flow multiple of 561.94 in trailing twelve-month period. Laboratory Analytical Instruments industry recorded net loss in trailing twelve months.
Company
-
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 3.78.
Laboratory Analytical Instruments industry's Price to Sales ratio is at 5.91.

Bio Rad Laboratories Inc Price to Book Ratio is at 1.43 lower than Industry Avg. of 336.39. and higher than S&P 500 Avg. of 0

• More on BIO's Valuation

•  Market Capitalization (Millions $) 9,684
•  Shares Outstanding (Millions) 28
•  Employees 8,030
•  Revenues (TTM) (Millions $) 2,562
•  Net Income (TTM) (Millions $) -1,326
•  Cash Flow (TTM) (Millions $) 17
•  Capital Exp. (TTM) (Millions $) -169
•  Total Debt (Millions $) 1,200
•  Dividend TTM ($) 0 $
•  Dividend Yield TTM (%) -
•  Revenue/Employee (TTM) $ 319,017
•  Net Income/Employee(TTM) $ -
•  Receivable Turnover Ratio (TTM) 5.58
•  Tangible Book Value (Per Share $) 213.40

•  Market Capitalization (Millions $) 9,684
•  Shares Outstanding (Millions) 28
•  Employees 8,030
•  Revenues (TTM) (Millions $) 2,562
•  Net Income (TTM) (Millions $) -1,326
•  Cash Flow (TTM) (Millions $) 17
•  Capital Exp. (TTM) (Millions $) -169


    BIO's Profitability Comparisons
Bio Rad Laboratories Inc achieved increase in profitability, due to increase in demand and cost control. Operating Margin grew in II. Quarter 2024 to 15.91 % from 7.33 % in I. Quarter.




Profitability by Segment
Life Science 7.62 %
Clinical Diagnostics 21.29 %



  Ratio
•   Capital Ratio (MRQ) 6.86
•  Total Debt to Equity (MRQ) 0.18
•  Tangible Leverage Ratio (MRQ) 0.47
•  Asset Turnover Ratio (TTM) 0.22
•  Inventory Turnover Ratio (TTM) 1.5



Bio Rad Laboratories Inc achieved increase in profitability, due to increase in demand and cost control. Operating Margin grew in II. Quarter 2024 to 15.91 % from 7.33 % in I. Quarter.



• More on BIO's Key Ratios





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com